Louise Proulx, Ph.D. Venture Partner
Louise Proulx holds a Ph.D. in physiology from Université Laval and pursued postdoctoral studies at the Karolinska Institute in Stockholm. She has close to 30 years’ experience in research and development management. She has held, over the years, scientific positions of increasing responsibilities, notably as Vice President, Scientific Affairs at Hoechst Marion Roussel Canada, Vice President, Therapeutic Product Development at BioChem Pharma Inc., Vice President, Business Development of Genome Quebec and Vice Principal Research at McGill University. She then returned to the pharmaceutical industry where she has been Vice President, Product Development at ViroChem Pharma Inc. She then became Vice-President, and Site Head, at Vertex Pharmaceuticals (Canada) Incorporated after the acquisition of ViroChem Pharma by Vertex Pharmaceuticals. As Chief Development Officer at Therillia Dr. Proulx oversees the development of therapeutic assets of interest to Therillia’s shareholders, including dalcetrapib.Dr. Proulx has been a member of several boards of directors over her career and she is currently a member of the board of directors of Diagnocure Inc., the Research Institute of the McGill University Health Center, Gestion Univalor, Verlyx Pharma and CQDM. Dr. Proulx is certified ICD.D by the Institute of Corporate Directors.